Continuous glucose monitoring in pregnant women with type 1 diabetes
The use of continuous glucose monitoring (CGM) has been increasing, especially in patients with type 1 diabetes, partly due to improved accuracy with lower mean amplitude relative difference (about 10%) with the newer or implantable sensors.
1,2 Most real-time subcutaneous sensors are approved for 7 days-except for the implantable sensor, which lasts 3 months-and require two calibrations per day.
1-3 One on-demand sensor is approved for 14 days and needs no calibrations. 2 Improved health outcomes, such as increased time in target and reduced hypoglycaemia, diabetic ketoacidosis, and glucose variability, and improved glucose control are reported with use of CGM in non-pregnant patients using multiple daily injections or insulin pumps.
2,4,5 Most international diabetes or medical organisations such as the American Diabetes Association, the European Association for the Study of Diabetes, the American Congress of Obstetricians and Gynecologists, and the American Association of Clinical Endocrinologists do not specifically recommend CGM use for all women in this high-risk population. 5, 6 Most recently, the Centers for Medicare and Medicaid Services in the USA have authorised payment for CGM in patients with diabetes who require insulin. 2 The use of real-time CGM in pregnancy associated with type 1 diabetes has not been evaluated properly in this high-risk group; 7 for industry, this failure to evaluate might be partly attributed to the litigious health-care environment in some industrialised countries. The studies reported to date have been observational or retrospective with small sample sizes. 7 In The Lancet, Denice Feig and colleagues 8 report their evaluation of health outcomes from the use of CGM in 325 women with type 1 diabetes (215 pregnant and 110 planning pregnancy) in the randomised, multicentre CONCEPTT trial. The primary outcome was change in glycated haemoglobin (HbA 1c ) from randomisation to 34 weeks' gestation in pregnant women, and to 24 weeks or conception in women planning pregnancy. The primary outcome of a between-group difference in HbA 1c of 0·5% was not achieved, although there was a small difference in HbA 1c in pregnant women using CGM (mean difference −0·19%, 95% CI −0·34 to −0·03; p=0·0207). Despite the small sample size and the finding of only a small between-group difference in HbA 1c , they document secondary outcomes of increased time in target (68% in pregnant CGM users vs 61% in pregnant control participants; p=0·0034) and reduced incidence of babies large for gestational age (odds ratio 0·51, 95% CI 0·28 to 0·90; p=0·0210) in this high-risk cohort of patients. Increasing time in target by making necessary changes in insulin dose (not recorded in this study) and reducing post-prandial hyperglycaemia through CGM data probably contributed to these improved neonatal outcomes, which might not be reflected in change in HbA 1c levels or overall good glucose control in pregnant women in the trial (at 34 weeks' gestation, mean HbA 1c was 6·35% [SD 0·57] in the intervention group and 6·53% [0·70] in the control group). Previous studies on intermittent CGM use in pregnancies complicated by diabetes have shown little or no effect on maternal and fetal outcomes. 7 The fact that CONCEPTT showed significant effects on the proportion of infants large for gestational age and on neonatal intensive care unit duration of stay with frequent CGM use is akin to studies in non-pregnant populations showing favourable outcomes with comparable CGM use. 5 We believe that the CONCEPTT results support CGM use during pregnancy for all women with type 1 diabetes and time in range might become an important measure in pregnancies associated with type 1 diabetes; thus endocrine and obstetric medical societies could consider advocating or recommending revising their guidelines accordingly.
Unfortunately, the primary endpoint of a betweengroup difference in HbA 1c of 0·5% was not achieved in this trial. It was discouraging to see no improvements in severe hypoglycaemia in this high-risk population. Of importance, the CGM group had more visits with providers (both scheduled and unscheduled), which might have contributed to the small improvement in HbA 1c . Despite a motivated population, CGM was not constant-70% of participants in the pregnant group and 77% in the planning pregnancy group used CGM for more than 75% of the time. Also, HbA 1c measurements were sent to the central laboratory infrequently (every 10-12 weeks) and around 20% of the samples were missing for various reasons, although HbA 1c measurements were done locally on a monthly basis in most centres. As highlighted by Feig and colleagues, 8 the CGM compliance was lower than that of more recent CGM studies, 9 which could explain the less than expected drop in HbA 1c . Additionally, 179 (55%) of the participants used insulin pumps, which might not represent the European type 1 diabetes population. The biggest drawback in the study is the absence of information about the frequency of self-monitoring of blood glucose and how it relates to improvements in HbA 1c in the control group. Studies from different registries have reported that the frequency of self-monitoring of blood glucose is associated with HbA 1c levels. 10 However, all women in the trial were required to obtain at least four capillary glucose tests daily to be eligible, and were advised to test levels at least seven times a day; pregnant women with diabetes typically perform seven to ten tests per day. Furthermore, a cost-benefit analysis from this study needs to justify use of CGM during pregnancy compared with self-monitoring alone.
Use of CGM alone does not alter insulin delivery; therefore, patient interventions are needed to reduce hypoglycaemia (despite nocturnal alarms or alerts) and hyperglycaemia. We believe that the use of integrated systems (pumps with CGM), in which insulin delivery is stopped automatically at or before a low sensor glucose level, reduces hypoglycaemia, especially overnight. 11, 12 Because hypoglycaemia, particularly at night, is a substantial concern in this high-risk population in whom the aim is to maintain lower HbA 1c and fasting glucose, 6 future studies need to evaluate the now approved hybrid closed-loop system 13 during pregnancies associated with type 1 diabetes, as well as new artificial pancreas systems that might reach the market.
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